Capricor Therapeutics Inc — Quarterly Financial Data (NASDAQ:CAPR) | MetaTrader

Open full chart

Financials

Overview Finanzbericht Statistics Dividends

Quarterly Annual

Dividends per share ————— — Dividend yield % ————— — Payout ratio % ————— —

Nachrichten

Oppenheimer conferma rating Outperform per Capricor, mantiene target a $54

Oppenheimer reiterates Outperform rating on Capricor stock, maintains $54 target

CAPR Updates FDA on Deramiocel BLA, Plans HOPE-3 CSR Filing in February

Capricor to submit HOPE-3 data to FDA for DMD therapy review

Cantor Fitzgerald ribadisce il rating su Capricor Therapeutics

Capricor Therapeutics stock rating reiterated by Cantor Fitzgerald

Cantor Fitzgerald conferma rating Overweight per le azioni Capricor

Cantor Fitzgerald reiterates Overweight rating on Capricor stock

Capricor Therapeutics Stock: A High Risk/High Reward Name (NASDAQ:CAPR)

Biotech Stocks' Dark Winter Is Over. What That Means For Investors.

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy Transcript

Piper Sandler conferma il rating di Capricor, la nomina top pick per il 2026